Premium
Fluorescent Imaging‐Guided Chemotherapy‐and‐Photodynamic Dual Therapy with Nanoscale Porphyrin Metal–Organic Framework
Author(s) -
Liu Wei,
Wang YongMei,
Li YuHao,
Cai ShiJiao,
Yin XueBo,
He XiWen,
Zhang YuKui
Publication year - 2017
Publication title -
small
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.785
H-Index - 236
eISSN - 1613-6829
pISSN - 1613-6810
DOI - 10.1002/smll.201603459
Subject(s) - photodynamic therapy , porphyrin , materials science , biocompatibility , doxorubicin , fluorescence , nanoscopic scale , fluorescence lifetime imaging microscopy , metal organic framework , nanotechnology , luminescence , drug delivery , biocompatible material , biomedical engineering , chemotherapy , photochemistry , chemistry , medicine , optoelectronics , organic chemistry , surgery , optics , physics , adsorption , metallurgy
Imaging‐guided therapy systems (IGTSs) are revolutionary techniques used in cancer treatment due to their safety and efficiency. IGTSs should have tunable compositions for bioimaging, a suitable size and shape for biotransfer, sufficient channels and/or pores for drug loading, and intrinsic biocompatibility. Here, a biocompatible nanoscale zirconium‐porphyrin metal–organic framework (NPMOF)‐based IGTS that is prepared using a microemulsion strategy and carefully tuned reaction conditions is reported. A high content of porphyrin (59.8%) allows the achievement of efficient fluorescent imaging and photodynamic therapy (PDT). The 1D channel of the Kagome topology of NPMOFs provides a 109% doxorubicin loading and pH‐response smart release for chemotherapy. The fluorescence guiding of the chemotherapy‐and‐PDT dual system is confirmed by the concentration of NPMOFs at cancer sites after irradiation with a laser and doxorubicin release, while low toxicity is observed in normal tissues. NPMOFs are established as a promising platform for the early diagnosis of cancer and initial therapy.